Reasoning
The upside comes from a tiny base, live field data, and a second vertical in hospitals. I see a credible path to several turns of equity appreciation if Serve replaces lost Uber volume, deepens healthcare contracts, and lifts revenue per robot with software, compliance, and workflow products. I cap the upside below top autonomy or software names because revenue is still services-heavy, pricing power is weak, and outside capital will likely absorb part of the operating win.